Abstract

BackgroundDirofilaria immitis is a life-threatening nematode spreading globally. Arsenical treatment is currently recommended for removal of adult worms. However, arsenical treatment is not available in some countries, and there are dogs that cannot tolerate the rapid kill of adult worms; therefore, alternative adulticide slow-kill treatments are needed. Criticisms against the use of these alternative protocols include the potential for allowing disease to progress and for the development of ML-resistant worms.MethodsThe efficacy of a protocol that includes semi-annual doses (i.e. every 6 months) of commercially available extended-release injectable moxidectin suspension (ProHeart® SR-12) with 30-day oral administration of doxycycline was studied in 20 dogs with naturally occurring D. immitis infections. Each dog received treatment with ProHeart® SR-12 (0.5 mg moxidectin/kg) by subcutaneous injection and oral doxycycline (10 mg/kg/bid × 30 days) every 6 months until two consecutive negative antigen test results were obtained. Pulmonary and cardiac evaluations were performed by radiographic and echocardiographic parameters. Physical examinations, complete blood counts, clinical chemistry profiles, microfilariae and antigen tests were performed periodically.ResultsAt enrollment, all dogs were positive for D. immitis antigen and 18 were microfilaremic. On day 30, microfilaremia counts decreased, and all dogs became amicrofilaremic by day 150. On day 180, 11 dogs were antigen-negative, and 7 more became negative by day 360. The two remaining antigen-positive dogs converted to negative by day 540 or 810. All antigen tests performed 180 days after the first negative test were negative. There was no decline in cardiac performance of the dogs throughout the study. Overall, pulmonary clinical conditions, presence of worms by echocardiography, and enlargement of caudal and main pulmonary arteries improved after treatment. Physical examinations, complete blood count results, and clinical chemistry profiles were within normal reference values. Respiratory conditions were improved, no damage to the heart was observed, and the treatment protocol was well tolerated by the animals.ConclusionsThis alternative adulticide treatment was efficacious and well tolerated in naturally infected dogs. The injectable formulation provides the advantage of having veterinarians able to administer, monitor, and assess the efficacy and condition of the dog throughout the treatment and post-treatment periods.

Highlights

  • Dirofilaria immitis is a life-threatening nematode spreading globally

  • Due to the unavailability of melarsomine-based products in Brazil and taking into consideration the increased prevalence of heartworm infection in the country [23, 24], the aim of the present study was to evaluate the efficacy of a heartworm-preventive protocol that includes the commercial formulation of an extendedrelease injectable moxidectin suspension (­ProHeart® Extended-release injectable moxidectin suspension (SR-12)) administered every six months plus cycles of 30-day treatment with oral doxycycline in dogs naturally infected with D. immitis

  • Eleven dogs became antigen-negative on day 180; 7 dogs became antigen-negative on day 360, and 1 dog on day 540 (Table 1)

Read more

Summary

Introduction

Dirofilaria immitis is a life-threatening nematode spreading globally. The number of infected dogs and the areas of the parasite distribution are increasing [1, 2] This increase is thought to be a consequence of the movement of infected dogs as well as global climate changes, which favor the spread of vector mosquito species [1, 3,4,5]. Treatment should target the elimination of all forms of the parasite as soon as possible with minimal treatment-related adverse effects. This will minimize progression of the lesions [2]

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.